The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
Department of Cardiovascular Surgery, University of Toyama, Toyama 930-0194, Japan.
Medicina (Kaunas). 2022 May 25;58(6):698. doi: 10.3390/medicina58060698.
The use of veno-arterial extracorporeal membrane oxygenation (ECMO) in patients with sepsis-induced cardiogenic shock has been reported, but the clinical implication of the Impella percutaneous axial-flow left ventricular assist device for such patients remains unknown. We had a 37-year-old man with septic shock and severely reduced cardiac function. Veno-arterial ECMO and concomitant Impella CP support ameliorated his end-organ dysfunction and achieved cardiac recovery, whereas severe mitral valve regurgitation due to chordal rupture developed later. Mitral valve replacement concomitant with ECMO removal as well as an Impella upgrade successfully treated the patient. ECMO and Impella support might be an effective therapeutic strategy for the bridge to recovery in patients with sepsis-induced cardiogenic shock; however, paying attention to mitral chordal rupture is highly encouraged.
已有研究报道,在感染性休克导致的心源性休克患者中使用静脉-动脉体外膜肺氧合(ECMO),但对于此类患者,经皮轴向血流 Impella 左心室辅助装置的临床意义尚不清楚。我们曾治疗过一名 37 岁男性患者,其患有感染性休克和严重的心功能减退。静脉-动脉 ECMO 和同时使用的 Impella CP 支持改善了他的终末器官功能障碍,并实现了心脏功能恢复,但后来出现了由于腱索断裂导致的严重二尖瓣反流。随后,二尖瓣置换术联合 ECMO 去除以及 Impella 升级成功治疗了该患者。ECMO 和 Impella 支持可能是感染性休克导致的心源性休克患者恢复的有效治疗策略;然而,强烈建议关注二尖瓣腱索断裂。